The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If it were Nasdaq or NYSE where u get quarterly updates that fine but when you're relying on annual updates it's a different kettle of fish..
Dave it's all there..no laziness..
And if Finncap were doing their job they should be looking ahead to 2022..Didn't Cathal say potentially they would do 20 CS in 2022?
Looks like a lazy bit of cut & paste to me, esp as they mention 'considerable upside to 28p' when the share price is already at 36p or thereabouts.
Bronx - I agree with you. CF believes the co is worth a lot more, so do investors, all the evidence is pointing towards solid and significant progress on all fronts. The in-house broker is ours so should be on our side (i.e. the company's and investors) and should give an honest view which is also aligned with the very positive views publicly expressed by CF and others in the company.
But Earache,Cathal said in a podcast in December that he understood the broker targets were low and said 'we better update them'
Well if the in-house broker is reiterating 28p then investors are banging their heads against a brick wall..
'Open Orphan (ORPH): Corp £3m contract to manufacture COVID-19 virus variant Open Orphan’s subsidiary, hVIVO, has signed a £3m contract with Imperial College London, as part of a Wellcome Trust funded initiative, to manufacture a SARS-CoV-2 challenge virus based on emerging variants of the virus. This could be used in future hVIVO-run challenge trials to allow direct comparisons of vaccines or antivirals against different COVID-19 variants. The manufacturing process is expected to complete before the end of 2021. hVIVO is currently running the world’s first COVID-19 characterisation study, using the original Wuhan-like D614G SARS-CoV-2 virus. We leave forecasts unchanged but with substantial room for upside to our target price of 28p, as this excludes potential monetisation of its non-core assets (HVO-001, Imutex and PrEP Bioharm).'
So if we're doing 10 CS this year and the quarantine unit is booked for all of 2022 why haven't the in house brokers upped their estimates??
Challenge study boom
Friel said the day for challenge studies has arrived as demand spiked in the wake of the pandemic. In previous years, hVIVO usually completed 2-3 challenge studies per year. However, that has increased to potentially 10 this year, with as many as 20 studies planned for next year.